Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
Aulos Bioscience, Inc.
Sotio Biotech Inc.
AstraZeneca
Mayo Clinic
M.D. Anderson Cancer Center
Neonc Technologies, Inc.
ImmunityBio, Inc.
Ocellaris Pharma, Inc.
Mayo Clinic
Regeneron Pharmaceuticals
Transgene
Incyte Corporation
University of Arizona
Memgen, Inc.
Pfizer
Sensei Biotherapeutics, Inc.
Incyte Corporation
University of Virginia
Incyte Corporation
University of Pittsburgh
Medicenna Therapeutics, Inc.
Marengo Therapeutics, Inc.
British Columbia Cancer Agency
Checkpoint Therapeutics, Inc.
Vincerx Pharma, Inc.
Mayo Clinic
ImaginAb, Inc.
Arcus Biosciences, Inc.
University of Florida
Massachusetts General Hospital
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics
Xencor, Inc.
Jules Bordet Institute
Incyte Corporation
Genocea Biosciences, Inc.
AbbVie
AbbVie
Incyte Corporation
Incyte Corporation
Incyte Corporation
MultiVir, Inc.
University of Southern California
ImmunoGen, Inc.
Yale University